Stock Commentary: Tokyo

01-06-1992 Comments (0)

3MAbbott LaboratoriesAcetaminophenAciphexActosAdvicorAlbuminAlbuminarAlendronate SodiumAllegraAllerganAlphaAlpharmaAmino AcidsAmpicillinAntihemophilic FactorApokynApomorphineAriceptAspirinAstraZenecaAtacandatorvastatinAvandiaAveloxAventis PharmaAzilectAzithromycinBASFBaxterBaxter Biopharma SolutionsBaxter Healthcare Corporation's BioPharma SolBaxter InternationalBaycolBayerBayerBenicarBetaganBiaxinBiaxin XLBoehringer IngelheimBristol-Myers SquibbBuminate 5%CabergolineCalanCancidasCandesartan CilexetilcapecitabineCardizem LACarvedilolCaspofungin AcetateCefditoren PivoxilceftriaxoneCelebrexcelecoxibCerivastatinCetirizineCevimeline HCLCiproCiprofloxacinCisaprideClarithromycinClaritinClopidogrelCoagulation Factor VIIaColesevelam HclCoregCrestorCyclosporineDiltiazemdocetaxeldonepezilDopamineDopamine HydrochlorideDostinexDrug DiscoveryEisaiEligardEndometrinEsomeprazole MagnesiumEtodolacEvoxacExelonFactiveFamotidineFexofenadine HclfinasterideFlomaxFloxinFlunisolideFluoxetine HclFosamaxFujisawa PharmaceuticalGatifloxacinGemifloxacin MesylateGenentechGenotropinGenzymeGlaxoSmithKlineGSKHealonHumulin 70-30Humulin NHumulin RHyalganHyaluronateinfliximabInjectionInsulinIsopto CarpineJanssen-CilagJohnson & JohnsonKetoprofenKyowa HakkoLansoprazoleLeuprolide AcetateLeuprolide Acetate InjectionLevaquinLevobunololLevofloxacinLillyLipitorLivaloLodineLoratadineLovastatinLupronMaxaltMeloxicamMerck KGaAMevacorMicardisMinoxidilMinoxidil TabletsMitsubishi PharmaMobicMometasone FuroateMonsantoMontelukast SodiumMoxifloxacinMoxifloxacin HCLNasal SprayNateglinideNeoralNexiumniacinNiacin XR and LovastatinNiaspanNovartisNovo NordiskNutropinNutropin AQNutropin DepotNystatinOfloxacinolmesartanOmalizumabOralOrudisOseltamivir PhosphatePepcidPfizerPharmaciaPhysostigmine SalicylatePilocarpinePioglitazonePitavastatinPlavixPravacholPravastatin SodiumPrednisolonePrevacidPrevacid NapraPACPrincipenProgesteronePrografProlastinPrometriumPropeciaPropulsidProscarProtopicProviscProzacQuetiapine FumarateRabeprazole SodiumranitidineRasagilineRecombinantRelenzaRemicadeRenagelRestasisRezulinRisperdalRisperdal ConstaRisperidoneRituxanrituximabRivastigmine TartrateRizatriptan BenzoateRocephinRocheRofecoxibrosiglitazonerosuvastatinSandimmuneSankyoSchering AgSchering PloughSchering-PloughSeroquelSerostimServierSevelamer HclShionogisildenafilSimvastatinSingulairSodium HyaluronateSolifenacin SuccinateSolvaySomatropinSomatropin [rDNA origin]SpectracefStarlixsyruptacrolimusTakeda Pharma GmbHTakeda PharmaceuticalsTakeda Pharmaceuticals AmericaTamifluTamsulosin HydrochlorideTaxotereTelmisartanTequinTravasolTroglitazoneTrophAmineTylenolUCBVerapamil HClVESIcareVfendViagraVigamoxVioxxVoriconazoleWelcholWyethXelodaXolairZanamivirZantacZithromaxZithromax InjectionZmaxZocorZonegranZonisamideZyrtec

TOKYO: stocks edged up slightly by 0.6% on the Nikkei Average as volume declined ahead of official company…

In order to access this content you need to be logged into the site and have an active subscription or trial subscription.  Please login, take a free trial or subscribe in order to continue reading.

A trial subscription will give you access to the latest news on The Pharma Letter for 7 days, in order to evaluate the paid service.   

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days

alt

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £70 per month or £720 per year

alt

  • No-limits access to our the site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. Its part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top